Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base
- PMID: 19636004
- DOI: 10.1200/JCO.2008.21.7018
Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base
Abstract
Background: The Commission on Cancer (CoC) designates cancer programs on the basis of the ability to provide a wide range of oncologic services and specialists. All CoC-approved hospitals are required to report their cancer diagnoses to the National Cancer Data Base (NCDB), and the cancer diagnoses at these hospitals account for approximately 70% of all new cancers diagnosed in the United States annually. However, it is unknown how CoC-approved programs compare with non-CoC-approved hospitals.
Methods: By using the American Hospital Association Annual Survey Database (2006), CoC-approved and non-CoC-approved hospitals were compared with respect to structural characteristics (ie, accreditations, geography, and oncologic services provided).
Results: Of the 4,850 hospitals identified, 1,412 (29%) were CoC-approved hospitals, and 3,438 (71%) were not CoC-approved hospitals. The proportion of CoC-approved hospitals varied at the state level from 0% in Wyoming to 100% in Delaware. Compared with non-CoC-approved hospitals, CoC-approved programs were more frequently accredited by the Joint Commission, designated as a Comprehensive Cancer Center by the National Cancer Institute, and affiliated with a medical school or residency program (P < .001). CoC-approved hospitals were less likely to be critical access hospitals or located in rural areas (P < .001). CoC-approved hospitals had more total beds and performed more operations per year (P < .001). CoC-approved programs more frequently offered oncology-related services, including screening programs, chemotherapy and radiation therapy services, and hospice/palliative care (P < .001).
Conclusion: Compared with non-CoC-approved hospitals, CoC-approved hospitals were larger, were more frequently located in urban locations, and had more cancer-related services available to patients. Studies that use the NCDB should acknowledge this limitation when relevant.
Similar articles
-
Relationship between cancer center accreditation and performance on publicly reported quality measures.Ann Surg. 2014 Jun;259(6):1091-7. doi: 10.1097/SLA.0000000000000542. Ann Surg. 2014. PMID: 24509202
-
Regional diversity and breadth of the National Cancer Data Base.Cancer. 1998 Dec 15;83(12):2649-58. Cancer. 1998. PMID: 9874473
-
The National Cancer Data Base and physician network.Top Health Inf Manage. 1997 Feb;17(3):45-59. Top Health Inf Manage. 1997. PMID: 10165387
-
The National Cancer Data Base report on completeness of American Joint Committee on Cancer staging in United States cancer facilities. The American College of Surgeons Commission on Cancer and the American Cancer Society.Cancer. 1996 Oct 1;78(7):1498-504. Cancer. 1996. PMID: 8839557 Review.
-
Using the NCDB for cancer care improvement: an introduction to available quality assessment tools.J Surg Oncol. 2009 Jun 15;99(8):488-90. doi: 10.1002/jso.21173. J Surg Oncol. 2009. PMID: 19466738 Review.
Cited by
-
Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers.Cancer Med. 2018 Oct;7(10):4932-4942. doi: 10.1002/cam4.1749. Epub 2018 Sep 2. Cancer Med. 2018. PMID: 30175515 Free PMC article.
-
The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).Breast Cancer Res Treat. 2024 Jan;203(2):245-256. doi: 10.1007/s10549-023-07125-5. Epub 2023 Oct 13. Breast Cancer Res Treat. 2024. PMID: 37833450 Free PMC article.
-
Identifying Modifiable and Non-modifiable Risk Factors of Readmission and Short-Term Mortality in Chondrosarcoma: A National Cancer Database Study.Ann Surg Oncol. 2022 Feb;29(2):1392-1408. doi: 10.1245/s10434-021-10802-8. Epub 2021 Sep 27. Ann Surg Oncol. 2022. PMID: 34570333
-
Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.JAMA Oncol. 2017 Jul 1;3(7):928-935. doi: 10.1001/jamaoncol.2016.6380. JAMA Oncol. 2017. PMID: 28152150 Free PMC article.
-
In Reply.Oncologist. 2015 Oct;20(10):1224. doi: 10.1634/theoncologist.2015-0243. Epub 2015 Oct 2. Oncologist. 2015. PMID: 26432821 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources